Pramipexole prolonged release (Mirapexin prolonged release®) is recommended as an option for use within NHS Wales for the treatment of the signs and symptoms of idiopathic Parkinson's disease, alone or in combination with levodopa. Pramipexole prolonged release should be initiated by a specialist experienced in the treatment of Parkinson's disease. AWMSG is of the opinion that pramipexole prolonged release may be suitable for shared care in accordance with appropriate local guidance. In order to limit potential errors, pramipexole prolonged release should be prescribed by brand as Mirapexin prolonged release®.